Weekly Recap: Moderna Phase III melanoma results and regulator talks

Moderna surged after positive Phase III melanoma data for its T-cell priming therapy and plans to expand oncology trials with Merck, alongside presentations of upcoming clinical data and regulator talks. Analysts reassessed ratings as the company pushes a five-vaccine oncology portfolio.